Massive study to reveal best diabetes drug for heart health
NCT ID NCT07417618
First seen Feb 20, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This study looks at medical records from 60,000 people with type 2 diabetes and obesity to compare three drugs (dulaglutide, semaglutide, and tirzepatide) against an older drug (sitagliptin). The goal is to see which one is best at preventing heart attacks, strokes, and death. The study does not involve new treatments or direct patient participation—it analyzes existing data to guide future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.